---
title: "Xinlong Holdings released its 2024 annual performance, with a net loss attributable to the parent company of 16.6127 million yuan, narrowing by 41.56%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/234198149.md"
description: "Xinlong Holdings released its 2024 annual report, with operating revenue of 523 million yuan, a year-on-year decrease of 11.53%. The net loss attributable to shareholders was 16.6127 million yuan, a year-on-year narrowing of 41.56%. The net loss after deducting non-recurring gains and losses was 21.6114 million yuan, a year-on-year narrowing of 50.53%. The basic loss per share was 0.0309 yuan"
datetime: "2025-04-02T10:06:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234198149.md)
  - [en](https://longbridge.com/en/news/234198149.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234198149.md)
generator: "portal-rs"
---

# Xinlong Holdings released its 2024 annual performance, with a net loss attributable to the parent company of 16.6127 million yuan, narrowing by 41.56%

According to the Zhitong Finance APP, Xinlong Holdings (000955.SZ) released its annual report for 2024, reporting an operating income of 523 million yuan, a year-on-year decrease of 11.53%. The net loss attributable to shareholders of the listed company was 16.6127 million yuan, a year-on-year narrowing of 41.56%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 21.6114 million yuan, a year-on-year narrowing of 50.53%. The basic loss per share was 0.0309 yuan

### Related Stocks

- [000955.CN](https://longbridge.com/en/quote/000955.CN.md)

## Related News & Research

- [MSC halts Russian Black Sea service after drone attack, Bloomberg News reports](https://longbridge.com/en/news/297066548.md)
- [Heidelberg Pharma, Huadong Medicine expand ADC collaboration to develop new drug candidates](https://longbridge.com/en/news/297291658.md)
- [Georgian Developer Origami Holding Launches $200M Mixed-Use Project on Batumi’s Ambassadori Island](https://longbridge.com/en/news/297327599.md)
- [Heidelberg Pharma says China NMPA clears HDP-101 combo trial in multiple myeloma](https://longbridge.com/en/news/297070749.md)
- [Priner, SEMEP attend EXPOSIBRAM 2026 mining conference in Brazil](https://longbridge.com/en/news/297365071.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**